Mingzhibenyuan Medical Technology

Mingzhi Benyuan is a Shanghai-based biotechnology company specializing in precision oncology through advanced molecular diagnostics. The company leverages next-generation sequencing (NGS) and liquid biopsy technologies to develop high-sensitivity assays for early cancer detection, therapy selection, and minimal residual disease (MRD) monitoring. Their platform integrates proprietary bioinformatics pipelines with clinical data to provide actionable insights for personalized cancer treatment. Mingzhi Benyuan's product portfolio includes comprehensive genomic profiling panels for various solid tumors, supporting both clinical decision-making and pharmaceutical research. The company is committed to improving patient outcomes by making advanced genomic testing more accessible and accurate within the Chinese healthcare market.